Key result
Cardiac resynchronisation therapy may benefit more heart failure patients than previously considered because mechanical systolic dyssynchrony exists irrespective of QRS duration.
Why the study?
Does cardiac resynchronisation therapy benefit heart failure patients with a normal QRS duration who have mechanical systolic dyssynchrony?
Does cardiac resynchronisation therapy benefit heart failure patients with a normal QRS duration who have mechanical systolic dyssynchrony?
Mechanical systolic dyssynchrony may identify heart failure patients with normal QRS duration who could benefit from cardiac resynchronisation therapy.
Mechanical systolic dyssynchrony exists in many patients with heart failure, irrespective of QRS duration, and so more patients may derive benefit from cardiac resynchronisation therapy than previously considered.
No takes yet. Share an insight, caveat, or question.
Angelo Auricchio (2004) studied this question. Cardiac resynchronisation therapy may benefit more heart failure patients than previously considered because mechanical systolic dyssynchrony exists irrespective of QRS duration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: